The UK’s 2019 exit from the European Union looms, and as the prospect of a ‘No Deal’ Brexit approaches, new challenges abound. One obstacle facing the national healthcare provider - and patients in both the UK and EU - is a potentially disrupted supply of medicines.
The UK’s 2019 exit from the European Union looms, and as the prospect of a ‘No Deal’ Brexit approaches, new challenges abound. One obstacle facing the national healthcare provider – and patients in both the UK and EU – is a potentially disrupted supply of medicines. Sjaak Vink, CEO and founder of TheSocialMedwork, examines the challenges for both the UK and the EU following Brexit, and asks how these issues might be overcome?
Market access delays for medicines is a growing concern internationally. Many bodies like the World Health Organization campaign for access to essential medicines for the developing world, but in reality, the lack of access affects patients from all socio-economic sectors.
This will undoubtedly be intensified in the aftermath of Brexit - not least because the monopolised pharmaceutical industry is notoriously inflexible. This means the potential impact of a No-Deal Brexit will be felt harder by this sector than perhaps any other industry.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.
